RayKnowChina Research Map
Shortlist

Peking Union Medical College / Chinese Academy of Medical Sciences

北京协和医学院/中国医学科学院

BeijingUniversity or health system

Hospitals that carry this university's name, added together, plus papers and trials that name only the university.

Research activity, not treatment quality. Not medical advice. How this works

Nasopharyngeal carcinoma

鼻咽癌
1.9%Leads about 1 in 53 of China's research papers on NPC ▲ from 0.8%

Led 45 of 2,375 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (23.4%).

Run this PubMed search

Open trials led
3
Research papers it led
45
Trials it led
12
Share of China's trials
2.0%
Share of the world's papers
1.4%
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 0020242025: 112025
ThemesImaging & AIRadiotherapy techniqueRecurrent / metastatic disease

Hospitals counted here

  1. National Cancer Center / Cancer Hospital, CAMS33
  2. Cancer Hospital CAMS – Shenzhen7
  3. Peking Union Medical College Hospital3
  4. Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College1
  5. National Cancer Center1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. A MRI-based radiomics model predicting radiation-induced temporal lobe injury in nasopharyngeal carcinoma.2022European radiologyRCT
  2. Radiotherapy Alone vs Radiotherapy With Concurrent Chemoradiotherapy and Survival of Patients With Low-Risk Nasopharyngeal Carcinoma.2023JAMA
  3. Application of multidimensional diffusion-weighted magnetic resonance imaging in nasopharyngeal carcinoma: a prospective study.2026Clinical radiology
  4. The prognostic value of intra- and peritumoral habitat analysis in nasopharyngeal carcinoma: combining IVIM and ASL.2026European radiology
  5. Cavernous sinus syndrome in a patient with occult nasopharyngeal carcinoma: A diagnostic challenge.2025Oral oncology
Trials on ClinicalTrials.gov6
  1. Real-World RAIRI-Guided Risk Stratification for Adjuvant Therapy Benefit After Chemoradiotherapy in NPCRecruitingNCT07618078Lead sponsorStart 2026-01
  2. RAIRI Model-Guided Adjuvant Therapy in Nasopharyngeal CarcinomaRecruitingNCT07590024Lead sponsorPhase 3Start 2026-05
  3. Nimotuzumab Combined With TGP as First-line Therapy in Patients With Recurrent/Metastatic Nasopharyngeal CarcinomaRecruitingNCT06509009Lead sponsorPhase 2Start 2024-08
  4. Toripalimab Combined With Different Platinum-Based Induction Chemotherapy Regimens for Locally Advanced Nasopharyngeal CarcinomaRecruitingNCT07362979Study sitePhase 2Start 2026-03
  5. LDRT Combined With Toripalimab and Chemotherapy for Recurrent/Metastatic NPCRecruitingNCT07325539Study sitePhase 2Start 2026-01
  6. Individualized Primary Clinical Target Volume Based on Margin Expansion for Nasopharyngeal CarcinomaRecruitingNCT07661771Study sitePhase 3Start 2026-07

PubMed searchClinicalTrials.gov

Oesophageal squamous cell carcinoma

食管鳞状细胞癌
6.8%Leads about 1 in 15 of China's research papers on ESCC

Led 200 of 2,923 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.9%).

Run this PubMed search

Open trials led
12
Research papers it led
200
Trials it led
36
Share of China's trials
6.3%
Share of the world's papers
4.6%
Papers led per year
2021: 0020212022: 0020222023: 3320232024: 1120242025: 002025
ThemesMolecular markers & genomicsNeoadjuvant & combined treatmentRadiotherapy

Hospitals counted here

  1. National Cancer Center / Cancer Hospital, CAMS184
  2. Cancer Hospital CAMS – Shenzhen7
  3. Peking Union Medical College Hospital4
  4. Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College1
  5. Carcinoma Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO/NCCES01 trial.2024Nature medicineRCTFree full text
  2. Effectiveness of S-1-Based Chemoradiotherapy in Patients 70 Years and Older With Esophageal Squamous Cell Carcinoma: A Randomized Clinical Trial.2023JAMA network openRCTFree full text
  3. First-line serplulimab or placebo plus chemotherapy in PD-L1-positive esophageal squamous cell carcinoma: a randomized, double-blind phase 3 trial.2023Nature medicineRCTFree full text
  4. Simultaneous integrated boost intensity-modulated radiotherapy with or without concurrent chemotherapy in patients with esophageal squamous cell carcinoma: A multicenter, open-label, randomized, phase III clinical trial.2026International journal of cancerRCT
  5. The efficacy and safety of nanoparticle albumin bound-paclitaxel-based regimen as second- or third-line treatment in patients with advanced esophageal squamous cell carcinoma.2023Thoracic cancerRCTFree full text
Trials on ClinicalTrials.gov6
  1. Radiotherapy Target Volume Delineation in Locally Advanced Esophageal Cancer in the Immunotherapy EraRecruitingNCT07858630Lead sponsorStart 2026-08
  2. Total Neoadjuvant Therapy Combined With Adebrelimab in Locally Advanced Resectable ESCCNot yet recruitingNCT06861777Lead sponsorPhase 2/Phase 3Start 2025-03
  3. Prognostic Analysis of Esophageal Cancer with Complete Pathological Response After Neoadjuvant TherapyNot yet recruitingNCT06889402Lead sponsorStart 2025-04
  4. Induction Chemoimmunotherapy Combined With Chemoradiotherapy in Esophageal CancerRecruitingNCT06421376Lead sponsorPhase 2Start 2024-05
  5. Neoadjuvant Comprehensive Treatment for Unresectable Esophageal CancerRecruitingNCT06430658Lead sponsorPhase 2Start 2024-04
  6. Optimizing Neoadjuvant Treatment Regimens for Locally Advanced Esophageal Squamous Cell CarcinomaRecruitingNCT06907602Lead sponsorPhase 2/Phase 3Start 2024-01

PubMed searchClinicalTrials.gov

Hepatocellular carcinoma

肝细胞癌
1.6%Leads about 1 in 63 of China's research papers on HCC

Led 233 of 14,765 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (5.5%).

Run this PubMed search

Open trials led
18
Research papers it led
233
Trials it led
48
Share of China's trials
3.3%
Share of the world's papers
0.8%
Papers led per year
2021: 0020212022: 3320222023: 2220232024: 0020242025: 002025
ThemesRecurrence & prognosisImaging, AI & early detectionImmunotherapy & targeted drugs

Hospitals counted here

  1. National Cancer Center / Cancer Hospital, CAMS103
  2. Peking Union Medical College Hospital65
  3. Cancer Hospital CAMS – Shenzhen6
  4. Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC Counted in the group total5
  5. Shanxi Cancer Hospital Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Microvascular invasion-negative hepatocellular carcinoma: Prognostic value of qualitative and quantitative Gd-EOB-DTPA MRI analysis.2023European journal of radiologyRCT
  2. Predictive factors of microvascular invasion in patients with intrahepatic mass-forming cholangiocarcinoma based on magnetic resonance images.2023Abdominal radiology (New York)RCT
  3. A nomogram model to predict prognosis of patients with hepatoblastoma.2022Pediatric blood & cancerRCT
  4. Transradial versus transfemoral access without closure device for transarterial chemoembolization in patients with hepatocellular carcinoma: a randomized trial.2022European radiologyRCT
  5. Diagnostic value of whole-tumor apparent diffusion coefficient map radiomics analysis in predicting early recurrence of solitary hepatocellular carcinoma ≤ 5 cm.2022Abdominal radiology (New York)RCT
Trials on ClinicalTrials.gov6
  1. Lenalidomide Plus Targeted Therapy and Immunotherapy for Refractory HCCRecruitingNCT07639138Lead sponsorPhase 2Start 2026-08
  2. 68Ga-NYM207 PET/CT Imaging in Hepatocellular CarcinomaRecruitingNCT07590336Lead sponsorPhase 1/Phase 2Start 2026-06
  3. A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of BRII-5395 in Combination With Sintilimab and Bevacizumab in Advanced Hepatitis B Virus Related Hepatocellular CarcinomaRecruitingNCT07557251Lead sponsorPhase 1Start 2026-08
  4. SHR-1701 Plus Apatinib for Second-Line Treatment in Targeted-Immune Pretreated Advanced Hepatocellular CarcinomaNot yet recruitingNCT07749859Lead sponsorPhase 2Start 2026-08
  5. Irreversible Electroporation Combined With Targeted Therapy and Immunotherapy for Advanced Hepatocellular CarcinomaRecruitingNCT07832006Lead sponsorPhase 2Start 2025-04
  6. β-alanine in the Treatment of Advanced Hepatocellular CarcinomaRecruitingNCT07317414Lead sponsorPhase 2Start 2025-12

PubMed searchClinicalTrials.gov

Stomach cancer

胃癌
2.1%Leads about 1 in 47 of China's research papers on Stomach cancer

Led 210 of 9,782 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (3.9%).

Run this PubMed search

Open trials led
6
Research papers it led
210
Trials it led
40
Share of China's trials
2.7%
Share of the world's papers
1.0%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 2220242025: 222025
ThemesChemotherapy & combined treatmentPeritoneal spread & advanced diseaseSurgery

Hospitals counted here

  1. National Cancer Center / Cancer Hospital, CAMS131
  2. Peking Union Medical College Hospital54
  3. Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College3
  4. Cancer Hospital CAMS – Shenzhen3
  5. Fuwai Hospital Counted in the group total2
  6. Carcinoma Hospital2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Effect of an Endoscopy Screening on Upper Gastrointestinal Cancer Mortality: A Community-Based Multicenter Cluster Randomized Clinical Trial.2025GastroenterologyRCT
  2. Long-Term Prognostic Analysis of Chemoradiation Therapy Versus Chemotherapy after D2 Resection for High-Risk Gastric Cancer: Results From a Prospective Randomized Control Study.2025International journal of radiation oncology, biology, physicsRCT
  3. Preoperative H. pylori Eradication Therapy Facilitates Precise Delineation in Early Gastric Cancer with Current H. pylori Infection.2024Digestive diseases (Basel, Switzerland)RCTFree full text
  4. Perioperative chemotherapy with docetaxel plus oxaliplatin and S-1 (DOS) versus oxaliplatin plus S-1 (SOX) for the treatment of locally advanced gastric or gastro-esophageal junction adenocarcinoma (MATCH): an open-label2024Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer AssociationRCTFree full text
  5. Autologous CIK cells combined with chemotherapy as the first-line treatment for locally advanced or metastatic gastric cancer is safe and feasible.2023Frontiers in immunologyRCTFree full text
Trials on ClinicalTrials.gov6
  1. Chemoradiotherapy and SHR-1701 in Patients With Unresectable Gastric CancerRecruitingNCT07689851Lead sponsorPhase 2Start 2026-07
  2. Exploratory Study on the Application of Molecular Residual Disease (MRD) in Postoperative Treatment of Gastric CancerRecruitingNCT07034742Lead sponsorEarly phase 1Start 2025-06
  3. Trifluridine/tipiracil (TAS-102), Bevacizumab, and Camrelizumab As Third-line or Later-line Therapy of Gastric CancerRecruitingNCT06711471Lead sponsorPhase 2Start 2024-11
  4. A Phase Ib/II Study of Adebrelimab in Combination with Capecitabine and Oxaliplatin in CancerRecruitingNCT06776770Lead sponsorPhase 1/Phase 2Start 2024-08
  5. Neo-Sequence 2:NCT Plus Anti-angiogenesis Therapy and Immunotherapy for LADGCRecruitingNCT06371586Lead sponsorPhase 2Start 2024-03
  6. Fruquintinib and Albumin-paclitaxel Combined With or Without PD-1 Antibody in 2nd-line Treatment of G/GEJ AdenocarcinomaRecruitingNCT06417892Lead sponsorStart 2024-04

PubMed searchClinicalTrials.gov

Hepatoblastoma

肝母细胞瘤
1.9%Leads about 1 in 51 of China's research papers on Hepatoblastoma

Led 3 of 154 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (13.6%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.7%
Papers led per year
2021: 0020212022: 2220222023: 0020232024: 0020242025: 002025

PubMed searchClinicalTrials.gov

Osteosarcoma

骨肉瘤
0.8%Leads under 1 in 100 of China's research papers on Osteosarcoma

Led 19 of 2,257 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.3%).

Run this PubMed search

Open trials led
0
Research papers it led
19
Trials it led
1
Share of China's trials
1.7%
Share of the world's papers
0.4%
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 442025

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. National Cancer Center / Cancer Hospital, CAMS8
  2. Peking Union Medical College Hospital4
  3. Cancer Hospital CAMS – Shenzhen1
  4. Fuwai Hospital, Peking Union Medical College1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Gastrointestinal stromal tumour

胃肠道间质瘤
1.3%Leads about 1 in 75 of China's research papers on Gastrointestinal stromal tumour ▼ from 3.9%

Led 7 of 523 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.3%).

Run this PubMed search

Open trials led
0
Research papers it led
7
Trials it led
1
Share of China's trials
1.4%
Share of the world's papers
0.4%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 332025

Hospitals counted here

  1. Peking Union Medical College Hospital6
  2. National Cancer Center / Cancer Hospital, CAMS1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Neuroblastoma

神经母细胞瘤
2.0%Leads about 1 in 49 of China's research papers on Neuroblastoma ▲ from 1.3%

Led 23 of 1,132 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.8%).

Run this PubMed search

Open trials led
1
Research papers it led
23
Trials it led
1
Share of China's trials
2.4%
Share of the world's papers
0.5%
Papers led per year
2021: 1120212022: 1120222023: 2220232024: 1120242025: 002025

Hospitals counted here

  1. Peking Union Medical College Hospital7
  2. National Cancer Center / Cancer Hospital, CAMS2
  3. Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC1
  4. Fuwai Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Ewing sarcoma

尤文肉瘤
1.8%Leads about 1 in 54 of China's research papers on Ewing sarcoma New since 2021

Led 3 of 163 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.6%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.3%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 112025

Hospitals counted here

  1. Peking Union Medical College Hospital1
  2. National Cancer Center / Cancer Hospital, CAMS1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Multiple myeloma

多发性骨髓瘤
4.8%Leads about 1 in 21 of China's research papers on Myeloma ▲ from 3.7%

Led 80 of 1,676 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.8%).

Run this PubMed search

Open trials led
31
Research papers it led
80
Trials it led
51
Share of China's trials
10.5%
Share of the world's papers
0.9%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 2220242025: 222025
ThemesDiagnosis, MRD & riskRelapse & resistanceDrug combinations

Hospitals counted here

  1. Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC47
  2. Peking Union Medical College Hospital27
  3. National Cancer Center / Cancer Hospital, CAMS Counted in the group total1
  4. Fuwai Hospital Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Health-related quality of life with daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible patients with newly diagnosed multiple myeloma: analysis 2025Annals of hematologyRCTFree full text
  2. Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS St2025Annals of hematologyRCTFree full text
  3. Bortezomib, Melphalan, and Prednisone With or Without Daratumumab in Transplant-ineligible Asian Patients With Newly Diagnosed Multiple Myeloma: The Phase 3 OCTANS Study.2023Clinical lymphoma, myeloma & leukemiaRCT
  4. Uncommon biphasic CAR-T expansion induces hemophagocytic lymphohistiocytosis-like syndrome and fatal multiple infections following BCMA CAR-T cell therapy: a case report.2024Journal for immunotherapy of cancerFree full text
  5. BCMA-BBZ-OX40 CAR-T Therapy Using an Instant Manufacturing Platform in Multiple Myeloma.2024Journal for immunotherapy of cancerFree full text
Trials on ClinicalTrials.gov6
  1. A Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019B in Patients With Relapsed/Refractory Multiple Myeloma.Not yet recruitingNCT07539233Lead sponsorEarly phase 1Start 2026-04
  2. Application Study of 68Ga-NOTA-BCMA Nanoantibody Imaging in Multiple MyelomaNot yet recruitingNCT07353554Lead sponsorN/AStart 2026-02
  3. CM336 Plus Isatuximab for Newly Diagnosed Multiple Myeloma With Renal ImpairmentRecruitingNCT07585760Lead sponsorPhase 2Start 2026-09
  4. Isa-VRD in TIE HRMMNot yet recruitingNCT07334535Lead sponsorPhase 4Start 2026-01
  5. MRD-Guided BCMA/CD3 Bispecific Antibody Treatment After Stem Cell Transplant for Newly Diagnosed Multiple MyelomaRecruitingNCT07409454Lead sponsorPhase 2Start 2026-07
  6. BR101 in Patients With Relapsed/Refractory Multiple MyelomaNot yet recruitingNCT07537049Lead sponsorPhase 1Start 2026-04

PubMed searchClinicalTrials.gov

B-cell acute lymphoblastic leukaemia (B-ALL)

B 细胞急性淋巴细胞白血病
6.7%Leads about 1 in 15 of China's research papers on B-ALL ▲ from 3.9%

Led 15 of 225 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.9%).

Run this PubMed search

Open trials led
12
Research papers it led
15
Trials it led
17
Share of China's trials
6.7%
Share of the world's papers
1.4%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 442025
ThemesChildrenPhiladelphia chromosome & geneticsCAR-T & cell therapy

Hospitals counted here

  1. Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC13
  2. Peking Union Medical College Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Molecular mechanisms of unique therapeutic potential of CUDC-907 for MEF2D fusion-driven BCP-ALL.2025Signal transduction and targeted therapyFree full text
  2. Total body irradiation versus chemotherapy myeloablative conditioning in B-cell acute lymphoblastic leukaemia patients with first complete remission.2025Scientific reportsFree full text
  3. Treatment of pro-B acute lymphoblastic leukemia and severe plaque psoriasis with anti-CD19 CAR T cells: a case report.2025Frontiers in immunologyFree full text
  4. Inaticabtagene autoleucel in adult relapsed or refractory B-cell acute lymphoblastic leukemia.2025Blood advancesFree full text
  5. Pneumocystis jirovecii Pneumonia Secondary to Blinatumomab Therapy: A Case Report.2024ChemotherapyFree full text
Trials on ClinicalTrials.gov6
  1. Immunotargeted Therapy Plus Low-Dose Chemotherapy in Newly Diagnosed Adult Ph+ B-ALLNot yet recruitingNCT07840976Lead sponsorPhase 2Start 2026-10
  2. Evaluation of the Safety and Efficacy of Sup19 CAR-T Cells in Patients With Previously Failed CD19-Targeted Therapy or CD19-Weakly Expressed Hematologic TumorsNot yet recruitingNCT07539610Lead sponsorPhase 1Start 2026-04
  3. Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL ProtocolRecruitingNCT06764238Lead sponsorPhase 2/Phase 3Start 2025-01
  4. Newly-diagnosed Pediatric Ph-positive B-ALL ProtocolRecruitingNCT07152041Lead sponsorPhase 3Start 2025-03
  5. A Clinical Study to Explore CT1195E in Patients With Relapsed/Refractory B-Cell NeoplasmsNot yet recruitingNCT07234045Lead sponsorPhase 1Start 2025-11
  6. Newly-diagnosed Low Risk Pediatric B-cell ALL ProtocolRecruitingNCT06882057Lead sponsorPhase 2/Phase 3Start 2025-03

PubMed searchClinicalTrials.gov

Aplastic anaemia

再生障碍性贫血
17.2%Leads about 1 in 6 of China's research papers on Aplastic anaemia ▲ from 13.3%

Led 71 of 412 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (17.2%).

Run this PubMed search

Open trials led
10
Research papers it led
71
Trials it led
49
Share of China's trials
50.5%
Share of the world's papers
4.5%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 442025
ThemesImmunosuppressive treatmentThrombopoietin drugsChildren

Hospitals counted here

  1. Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC48
  2. Peking Union Medical College Hospital16
  3. National Cancer Center / Cancer Hospital, CAMS3

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Efficacy and safety of immunosuppressive therapy versus cyclosporine combined with avatrombopag in older adults with severe aplastic anemia: a multicenter prospective study.2025Blood cancer journalRCTFree full text
  2. Eltrombopag with or without Tacrolimus for relapsed/refractory acquired aplastic anaemia: a prospective randomized trial.2023Blood cancer journalRCTFree full text
  3. Adding recombinant human thrombopoietin to cyclosporine A and hetrombopag enhances the early hematologic response in transfusion-dependent non-severe aplastic anemia: a retrospective study.2025Hematology (Amsterdam, Netherlands)
  4. Platelet transfusion refractoriness within one month post-hematopoietic stem cell transplantation does not impair survival in aplastic anemia patients after engraftment: a propensity score-matched analysis.2025Frontiers in immunologyFree full text
  5. Somatic mutations and the efficacy of immunosuppressive therapy in severe/very severe aplastic anemia and transfusion-dependent nonsevere aplastic anemia.2025Annals of hematologyFree full text
Trials on ClinicalTrials.gov6
  1. Phase I/II Study of Anti-CD38 Monoclonal Antibody in Refractory Severe Aplastic AnemiaRecruitingNCT07714512Lead sponsorPhase 1/Phase 2Start 2026-06
  2. Adverse Effects of ATG/ALG Therapy in Aplastic AnemiaRecruitingNCT07461116Lead sponsorStart 2026-02
  3. Reproductive and Mental Health of Patients With Aplastic AnemiaRecruitingNCT06936930Lead sponsorStart 2025-03
  4. Brain Cognitive Network Abnormalities in Anemia Patients Using fNIRSRecruitingNCT07578675Lead sponsorStart 2025-10
  5. The Safety and Efficacy of Daratumumab in Patients With Refractory Aplastic AnemiaRecruitingNCT07287228Lead sponsorPhase 1/Phase 2Start 2025-12
  6. Dose-attenuated IST and Hetrombopag in Elderly (≥65 Years) Patients With Severe Aplastic AnemiaRecruitingNCT07010237Lead sponsorPhase 2Start 2025-02

PubMed searchClinicalTrials.gov

Haemophagocytic lymphohistiocytosis (HLH)

噬血细胞性淋巴组织细胞增生症
2.5%Leads about 1 in 40 of China's research papers on HLH

Led 10 of 399 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (22.3%).

Run this PubMed search

Open trials led
0
Research papers it led
10
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.6%
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 2220242025: 112025
ThemesLymphoma & cancer-related HLHGenetics & inherited formsDiagnosis & prognosis

Hospitals counted here

  1. Peking Union Medical College Hospital7
  2. Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC Counted in the group total1
  3. Fuwai Hospital Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Uncommon biphasic CAR-T expansion induces hemophagocytic lymphohistiocytosis-like syndrome and fatal multiple infections following BCMA CAR-T cell therapy: a case report.2024Journal for immunotherapy of cancerFree full text
  2. CHOP is insufficient for newly-diagnosed subcutaneous panniculitis-like T-cell lymphoma patients: a retrospective study of 32 patients in China.2025BMC cancerFree full text
  3. Disseminated tuberculosis complicated by intramuscular abscesses, meningoencephalitis, and hemophagocytic lymphohistiocytosis: a case report.2024BMC infectious diseasesFree full text
  4. Case Report: Missing zinc finger domains: hemophagocytic lymphohistiocytosis in a GATA2 deficiency patient triggered by non-tuberculous mycobacteriosis.2023Frontiers in immunologyFree full text
  5. Management of hemophagocytic lymphohistiocytosis in pregnancy: Case series study and literature review.2022The journal of obstetrics and gynaecology researchFree full text
Trials on ClinicalTrials.gov2
  1. A Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis (Also Known as Macrophage Activation Syndrome [MAS])RecruitingNCT07208058Study sitePhase 3Start 2025-11
  2. A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic Characteristics, and Immunogenicity of Plonmarlimab in Subjects With Rheumatic and Immunological Disease-associated Haemophagocytic Lymphohistiocytosis (HLH) (Also Known as Macrophage Activation Syndrome (MAS))CompletedNCT07034209Study sitePhase 2Start 2023-04

PubMed searchClinicalTrials.gov

Beta thalassaemia

β 地中海贫血
1.3%Leads about 1 in 78 of China's research papers on Beta thalassaemia ▲ from 0.6%

Led 4 of 312 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (9.9%).

Run this PubMed search

Open trials led
0
Research papers it led
4
Trials it led
6
Share of China's trials
12.8%
Share of the world's papers
0.2%
Papers led per year
2021: 2220212022: 1120222023: 0020232024: 0020242025: 112025

Hospitals counted here

  1. Peking Union Medical College Hospital1
  2. National Cancer Center / Cancer Hospital, CAMS1
  3. Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Haemophilia A

血友病 A
15.8%Leads about 1 in 6 of China's research papers on Haemophilia A ▼ from 25.5%

Led 43 of 272 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (15.8%).

Run this PubMed search

Open trials led
5
Research papers it led
43
Trials it led
8
Share of China's trials
9.8%
Share of the world's papers
1.5%
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 1120242025: 332025

Hospitals counted here

  1. Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC25
  2. Peking Union Medical College Hospital17
  3. Fuwai Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Single-dose rituximab plus glucocorticoid versus cyclophosphamide plus glucocorticoid in patients with newly diagnosed acquired hemophilia A: A multicenter, open-label, randomized noninferiority trial.2024American journal of hematologyRCT
  2. Efficacy, safety and bioequivalence of the human-derived B-domain-deleted recombinant factor VIII TQG202 for prophylaxis in severe haemophilia A patients.2022Haemophilia : the official journal of the World Federation of HemophiliaRCT
  3. The effectiveness and safety of various treatments for hemophilia in China: a literature review and evidence mapping.2025Hematology (Amsterdam, Netherlands)
  4. The efficacy, safety, and pharmacokinetics of N8-GP in previously treated Chinese patients with haemophilia A: results from the phase 3b pathfinder10 study.2025Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis
  5. Disease Burden and Treatment Patterns Amongst Patients with Haemophilia A in China: A Retrospective Database Analysis Study.2025Advances in therapy
Trials on ClinicalTrials.gov6
  1. Safety and Efficacy Study of NGGT003 in Hemophilia A PatientsRecruitingNCT06238908Lead sponsorEarly phase 1Start 2024-01
  2. ITI Using SCT800 Alone or Combining Daratumumab in Hemophilia A Adolescents and Adults With High Titer InhibitorRecruitingNCT05888870Lead sponsorPhase 4Start 2023-11
  3. A Study of FVIII Gene Therapy for Hemophilia ARecruitingNCT05454774Lead sponsorEarly phase 1Start 2022-07
  4. Gene Therapy for Chinese Hemophilia ARecruitingNCT04728841Lead sponsorN/AStart 2021-03
  5. National Longitudinal Cohort of Hematological DiseasesRecruitingNCT04645199Lead sponsorStart 2020-12
  6. Safety of KN057 Prophylaxis in Patients With Haemophilia A or BRecruitingNCT07545395Study sitePhase 3Start 2026-03

PubMed searchClinicalTrials.gov

Thrombotic thrombocytopenic purpura

血栓性血小板减少性紫癜
1.6%Leads about 1 in 64 of China's research papers on Thrombotic thrombocytopenic purpura ▼ from 26.1%

Led 1 of 64 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (9.4%).

Run this PubMed search

Open trials led
0
Research papers it led
1
Trials it led
1
Share of China's trials
16.7%
Share of the world's papers
0.1%
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

Hospitals counted here

  1. Peking Union Medical College Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led1
  1. Clinical presentation and management of acquired thrombotic thrombocytopenic purpura: A case series of 55 patients.2021Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy
Trials on ClinicalTrials.gov2
  1. Efficacy and Safety of Bortezomib as First-line Treatment of Acquired TTPStatus unknownNCT05135442Lead sponsorPhase 4Start 2021-12
  2. A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic PurpuraActive, not recruitingNCT04683003Study sitePhase 3Start 2021-04

PubMed searchClinicalTrials.gov

Fanconi anaemia

范可尼贫血
7.3%Leads about 1 in 14 of China's research papers on Fanconi anaemia ▲ from 3.7%

Led 5 of 68 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.8%).

Run this PubMed search

Open trials led
0
Research papers it led
5
Trials it led
1
Share of China's trials
50.0%
Share of the world's papers
1.1%
Papers led per year
2021: 2220212022: 1120222023: 2220232024: 0020242025: 002025

Hospitals counted here

  1. Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC3
  2. National Cancer Center / Cancer Hospital, CAMS1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Neuromyelitis optica spectrum disorder (NMOSD)

视神经脊髓炎谱系疾病
2.1%Leads about 1 in 49 of China's research papers on NMOSD

Led 10 of 485 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (10.5%).

Run this PubMed search

Open trials led
0
Research papers it led
10
Trials it led
1
Share of China's trials
1.3%
Share of the world's papers
0.5%
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 1120242025: 112025
ThemesAntibodies & diagnosisImagingOptic nerve & vision

Hospitals counted here

  1. Peking Union Medical College Hospital8
  2. Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

IgG4-related disease

IgG4相关性疾病
19.1%Leads about 1 in 5 of China's research papers on IgG4-RD

Led 47 of 246 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (19.1%).

Run this PubMed search

Open trials led
7
Research papers it led
47
Trials it led
21
Share of China's trials
48.8%
Share of the world's papers
4.0%
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 1120242025: 002025
ThemesTreatment & relapseDiagnosis & look-alikesHead, eye socket & salivary glands

Hospitals counted here

  1. Peking Union Medical College Hospital47

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Withdrawal of immunosuppressants and low-dose steroids in patients with stable IgG4-RD (WInS IgG4-RD): an investigator-initiated, multicentre, open-label, randomised controlled trial.2024Annals of the rheumatic diseasesRCT
  2. Genome-wide association studies reveal new insights into the genetic basis of IgG4-related disease in the Chinese Han population.2026Annals of the rheumatic diseases
  3. Differences in clinical characteristics of IgG4-related disease across age groups: a prospective study of 737 patients.2021Rheumatology (Oxford, England)
  4. Phenotype, function and clinical significance of innate lymphoid cells in immunoglobulin G4-related disease.2022Rheumatology (Oxford, England)
  5. Evaluating and predicting disease damage accumulation of IgG4-RD over ten years: utility of the IgG4-related Disease Damage Index.2026Clinical and experimental rheumatology
Trials on ClinicalTrials.gov6
  1. Nebulized UC-EVs for Recurrent or Refractory IMIDs With Lung InvolvementNot yet recruitingNCT07806045Lead sponsorEarly phase 1Start 2026-10
  2. Tripterygium Wilfordii Plus Prednisone for Active IgG4-Related DiseaseNot yet recruitingNCT07878585Lead sponsorPhase 2Start 2026-09
  3. A Randomized Controlled Study of the Efficacy and Safety of Lenalidomide in the Treatment of Active IgG4-related DiseaseRecruitingNCT07068165Lead sponsorPhase 2/Phase 3Start 2025-07
  4. A Study on the Effect of MRD Detected by FAPI PET / CT on the Recurrence of IgG4-RDRecruitingNCT07104058Lead sponsorN/AStart 2025-05
  5. Treatment Strategies for IgG4-RD Patients With Superficial Organ InvolvementRecruitingNCT05789030Lead sponsorN/AStart 2022-07
  6. National Registry of IgG4-RD in ChinaRecruitingNCT03023371Lead sponsorStart 2016-12

PubMed searchClinicalTrials.gov

Myasthenia gravis

重症肌无力
1.2%Leads about 1 in 83 of China's research papers on Myasthenia gravis ▼ from 2.9%

Led 6 of 499 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.6%).

Run this PubMed search

Open trials led
0
Research papers it led
6
Trials it led
1
Share of China's trials
1.1%
Share of the world's papers
0.3%
Papers led per year
2021: 1120212022: 1120222023: 2220232024: 1120242025: 002025
ThemesThymus & thymectomyAntibodies & diagnosis

Hospitals counted here

  1. Peking Union Medical College Hospital6

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Moyamoya disease

烟雾病
2.8%Leads about 1 in 36 of China's research papers on Moyamoya ▲ from 1.8%

Led 10 of 356 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (19.9%).

Run this PubMed search

Open trials led
0
Research papers it led
10
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.8%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 552025
ThemesGeneticsImaging & blood flowStroke & bleeding outcomes

Hospitals counted here

  1. Peking Union Medical College Hospital9

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Anti-NMDA receptor encephalitis

抗 NMDA 受体脑炎
1.1%Leads about 1 in 88 of China's research papers on Anti-NMDA receptor encephalitis ▼ from 7.3%

Led 3 of 264 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (10.2%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.4%
Papers led per year
2021: 1120212022: 1120222023: 1120232024: 0020242025: 002025

Hospitals counted here

  1. Peking Union Medical College Hospital3

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Takayasu arteritis

大动脉炎
21.9%Leads about 1 in 5 of China's research papers on Takayasu arteritis ▼ from 34.3%

Led 41 of 187 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (24.6%).

Run this PubMed search

Open trials led
0
Research papers it led
41
Trials it led
1
Share of China's trials
4.0%
Share of the world's papers
5.1%
Papers led per year
2021: 0020212022: 0020222023: 2220232024: 1120242025: 222025

Hospitals counted here

  1. Peking Union Medical College Hospital27
  2. Fuwai Hospital13
  3. Fuwai Hospital, Peking Union Medical College1
  4. Fuwai Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Mycophenolate mofetil plus methotrexate versus cyclophosphamide with sequential azathioprine for treatment of Takayasu arteritis.2025Annals of the rheumatic diseasesRCT
  2. Validation and clinical application of 2022 ACR/EULAR criteria for Takayasu arteritis in a large Chinese cohort.2025Rheumatology (Oxford, England)
  3. Comparative Efficacy of Secukinumab Versus Tumor Necrosis Factor Inhibitors for the Treatment of Takayasu Arteritis.2023Arthritis & rheumatology (Hoboken, N.J.)
  4. Association between premature vascular smooth muscle cells senescence and vascular inflammation in Takayasu's arteritis.2024Annals of the rheumatic diseases
  5. Alterations of Gut Microbiome, Metabolome, and Lipidome in Takayasu Arteritis.2023Arthritis & rheumatology (Hoboken, N.J.)
Trials on ClinicalTrials.gov6
  1. Pulmonary Artery Involvement in Takayasu's ArteritisCompletedNCT03189602Lead sponsorStart 2014-01
  2. Efficacy and Safety of Vunakizumab and Ivarmacitinib in the Treatment of Active Takayasu's ArteritisNot yet recruitingNCT07451665Study sitePhase 4Start 2026-04
  3. The Efficacy and Safety of Deucravacitinib in Takayasu's ArteritisNot yet recruitingNCT07013838Study sitePhase 4Start 2025-06
  4. Comparison of Tofacitinib and Prednisolone in the Treatment of Active Takayasu's ArteritisStatus unknownNCT05749666Study sitePhase 3Start 2023-01
  5. Comparison of Mycophenolate Mofetil and Cyclophosphamide for Active Takayasu's ArteritisCompletedNCT03096275Study sitePhase 3Start 2017-03
  6. American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Diagnostic and Classification Criteria for Primary Systemic VasculitisStatus unknownNCT01066208Study siteStart 2011-01

PubMed searchClinicalTrials.gov

Idiopathic pulmonary fibrosis

特发性肺纤维化
2.8%Leads about 1 in 35 of China's research papers on Idiopathic pulmonary fibrosis

Led 28 of 989 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.3%).

Run this PubMed search

Open trials led
0
Research papers it led
28
Trials it led
1
Share of China's trials
1.4%
Share of the world's papers
0.7%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 552025

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Peking Union Medical College Hospital18
  2. National Cancer Center / Cancer Hospital, CAMS1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial.2025Nature medicineRCT
  2. Hypertension in idiopathic pulmonary fibrosis: evidence of immune and genetic links from clinical and genomic analyses.2025Respiratory research
  3. Clinical significance of anti-neutrophil cytoplasmic antibody in idiopathic interstitial pneumonia: a retrospective observational study.2025BMC pulmonary medicine
  4. Clinical analysis of patients with idiopathic pulmonary fibrosis concurrent with surgery resectable lung cancer: a retrospective cohort study from perspective of ILD physicians.2025BMC pulmonary medicine
  5. The impact of psoriasis on idiopathic pulmonary fibrosis: a two-sample Mendelian randomization study.2025International journal of dermatology
Trials on ClinicalTrials.gov6
  1. Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)RecruitingNCT07687459Study sitePhase 3Start 2026-09
  2. SC1011 Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF)RecruitingNCT06125327Study sitePhase 2/Phase 3Start 2023-06
  3. 68Ga-BMV101 PET/CT in Patients With Idiopathic Pulmonary FibrosisStatus unknownNCT02485886Lead sponsorEarly phase 1Start 2015-01
  4. Menstrual Blood-Derived Mesenchymal Stem Cell Injection (SC01009) in the Treatment of Idiopathic Pulmonary FibrosisNot yet recruitingNCT07131150Study sitePhase 2Start 2025-08
  5. Evaluating the Efficacy and Safety of of HSK44459 in People With Idiopathic Pulmonary FibrosisCompletedNCT06764862Study sitePhase 2Start 2025-01
  6. A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With NerandomilastActive, not recruitingNCT06238622Study sitePhase 3Start 2024-09

PubMed searchClinicalTrials.gov

Lymphangioleiomyomatosis

肺淋巴管平滑肌瘤病
31.1%Leads about 1 in 3 of China's research papers on Lymphangioleiomyomatosis ▼ from 50.0%

Led 14 of 45 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (31.1%).

Run this PubMed search

Open trials led
0
Research papers it led
14
Trials it led
2
Share of China's trials
100.0%
Share of the world's papers
5.7%
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 1120242025: 222025

Hospitals counted here

  1. Peking Union Medical College Hospital14

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症
6.6%Leads about 1 in 15 of China's research papers on Amyotrophic lateral sclerosis

Led 51 of 779 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.3%).

Run this PubMed search

Open trials led
0
Research papers it led
51
Trials it led
1
Share of China's trials
1.8%
Share of the world's papers
0.8%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 2220242025: 112025

Hospitals counted here

  1. Peking Union Medical College Hospital44
  2. Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Spinal muscular atrophy

脊髓性肌萎缩症
7.3%Leads about 1 in 14 of China's research papers on Spinal muscular atrophy ▲ from 3.7%

Led 4 of 55 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (29.1%).

Run this PubMed search

Open trials led
1
Research papers it led
4
Trials it led
1
Share of China's trials
3.3%
Share of the world's papers
0.7%
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 0020242025: 112025

Hospitals counted here

  1. Peking Union Medical College Hospital3

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Fabry disease

法布雷病
5.5%Leads about 1 in 18 of China's research papers on Fabry disease ▼ from 9.1%

Led 4 of 73 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (12.3%).

Run this PubMed search

Open trials led
1
Research papers it led
4
Trials it led
1
Share of China's trials
7.1%
Share of the world's papers
0.5%
Papers led per year
2021: 2220212022: 1120222023: 0020232024: 1120242025: 002025

Hospitals counted here

  1. Peking Union Medical College Hospital2
  2. Fuwai Hospital1
  3. Fuwai Hospital, Peking Union Medical College1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Duchenne muscular dystrophy

杜氏肌营养不良
1.9%Leads about 1 in 53 of China's research papers on Duchenne muscular dystrophy

Led 4 of 213 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (10.8%).

Run this PubMed search

Open trials led
0
Research papers it led
4
Trials it led
3
Share of China's trials
15.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 0020222023: 2220232024: 2220242025: 002025

Hospitals counted here

  1. Peking Union Medical College Hospital2
  2. Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led4
  1. Prevalence of Neutralizing Antibodies Against AAV Serotypes 2 and 9 in Healthy Participants from Multiple Centers Across China and Patients with DMD/BMD.2024Human gene therapy
  2. Generalizable anchor aptamer strategy for loading nucleic acid therapeutics on exosomes.2024EMBO molecular medicine
  3. Identification and characterization of two DMD pedigrees with large inversion mutations based on a long-read sequencing pipeline.2023European journal of human genetics : EJHG
  4. Forced activation of dystrophin transcription by CRISPR/dCas9 reduced arrhythmia susceptibility via restoring membrane Nav1.5 distribution.2023Gene therapy
Trials on ClinicalTrials.gov6
  1. A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of BBM-D101 in the Treatment of Duchenne Muscular Dystrophy.RecruitingNCT07058662Study sitePhase 1/Phase 2Start 2025-07
  2. A Study to Evaluate the Safety and Tolerability of RAG-18 in Pediatric Patients With Duchenne Muscular DystrophyActive, not recruitingNCT07282652Lead sponsorEarly phase 1Start 2025-12
  3. A Study to Evaluate the Safety and Tolerability of GEN6050X in Duchenne Muscular Dystrophy.Active, not recruitingNCT06392724Lead sponsorEarly phase 1Start 2024-07
  4. Bisoprolol in DMD Early CardiomyopathyStatus unknownNCT03779646Lead sponsorPhase 2/Phase 3Start 2019-01
  5. Phase 3 Trial of Pamrevlumab or Placebo in Combination With Systemic Corticosteroids in Participants With Ambulatory DMDTerminatedNCT04632940Study sitePhase 3Start 2021-03
  6. Phase 3 Trial of Pamrevlumab or Placebo With Systemic Corticosteroids in Participants With Non-ambulatory Duchenne Muscular Dystrophy (DMD)TerminatedNCT04371666Study sitePhase 3Start 2020-08

PubMed searchClinicalTrials.gov

Behçet disease

白塞病
22.9%Leads about 1 in 4 of China's research papers on Behçet disease ▲ from 15.0%

Led 56 of 245 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (22.9%).

Run this PubMed search

Open trials led
2
Research papers it led
56
Trials it led
6
Share of China's trials
35.3%
Share of the world's papers
4.3%
Papers led per year
2021: 0020212022: 1120222023: 3320232024: 1120242025: 002025

Hospitals counted here

  1. Peking Union Medical College Hospital49
  2. Fuwai Hospital4
  3. Children's Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College1
  4. Children's Hospital, Peking Union Medical College1
  5. Plastic Surgery Hospital1
  6. Fuwai Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

IgA nephropathy

IgA 肾病
0.9%Leads under 1 in 100 of China's research papers on IgA nephropathy ▼ from 2.4%

Led 7 of 736 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (9.4%).

Run this PubMed search

Open trials led
0
Research papers it led
7
Trials it led
1
Share of China's trials
0.9%
Share of the world's papers
0.4%
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 1120242025: 222025

Hospitals counted here

  1. Peking Union Medical College Hospital5

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Gaucher disease

戈谢病
3.3%Leads about 1 in 30 of China's research papers on Gaucher disease ▼ from 7.7%

Led 1 of 30 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.7%).

Run this PubMed search

Open trials led
0
Research papers it led
1
Trials it led
1
Share of China's trials
8.3%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

Hospitals counted here

  1. Peking Union Medical College Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Osteogenesis imperfecta

成骨不全症
17.2%Leads about 1 in 6 of China's research papers on Osteogenesis imperfecta ▼ from 26.2%

Led 17 of 99 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (17.2%).

Run this PubMed search

Open trials led
0
Research papers it led
17
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
2.2%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 3320242025: 222025

Hospitals counted here

  1. Peking Union Medical College Hospital14

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Primary biliary cholangitis

原发性胆汁性胆管炎
8.0%Leads about 1 in 12 of China's research papers on Primary biliary cholangitis ▲ from 4.7%

Led 24 of 300 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (12.0%).

Run this PubMed search

Open trials led
1
Research papers it led
24
Trials it led
2
Share of China's trials
4.0%
Share of the world's papers
2.4%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 442025

Hospitals counted here

  1. Peking Union Medical College Hospital22

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Clinical characteristics of dyslipidemia in patients with primary biliary cholangitis: a single-center experience in China.2025Clinical rheumatology
  2. Postpartum may be a risk factor for biochemical flares in patients with primary biliary cholangitis: A single-center experience.2025Clinical rheumatology
  3. Prediction of primary biliary cholangitis among health check-up population with anti-mitochondrial M2 antibody positive.2025Clinical and molecular hepatology
  4. Clinical characteristics of primary biliary cirrhosis - idiopathic inflammatory myopathy overlap syndrome: A single center study.2025The American journal of the medical sciences
  5. Risk of comorbidity of autoimmune liver disease in patients with inflammatory bowel disease: A single-center case-control study in China.2024Journal of digestive diseases
Trials on ClinicalTrials.gov5
  1. Clinical Research of Tapering UDCA in PBC Patients With a Complete ResponseRecruitingNCT04650243Lead sponsorPhase 4Start 2020-01
  2. Fenofibrate for Compensated Cirrhosis Patients With Primary Biliary CholangitisRecruitingNCT05749822Study sitePhase 2/Phase 3Start 2023-02
  3. Efficacy and Safety Study of Allogenic Mesenchymal Stem Cells for Patients With Refractory Primary Biliary CirrhosisStatus unknownNCT01440309Lead sponsorPhase 1Start 2011-11
  4. CS0159 in Chinese Patients With PBC (Primary Biliary Cholangitis)Active, not recruitingNCT05896124Study sitePhase 2Start 2023-08
  5. Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary CholangitisActive, not recruitingNCT06174402Study sitePhase 2/Phase 3Start 2023-08

PubMed searchClinicalTrials.gov

Primary sclerosing cholangitis

原发性硬化性胆管炎
6.0%Leads about 1 in 17 of China's research papers on Primary sclerosing cholangitis ▲ from 4.1%

Led 6 of 100 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (7.0%).

Run this PubMed search

Open trials led
0
Research papers it led
6
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.6%
Papers led per year
2021: 2220212022: 0020222023: 0020232024: 2220242025: 002025

Hospitals counted here

  1. Peking Union Medical College Hospital3
  2. Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Congenital diaphragmatic hernia

先天性膈疝
8.3%Leads about 1 in 12 of China's research papers on Congenital diaphragmatic hernia New since 2021

Led 5 of 60 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (18.3%).

Run this PubMed search

Open trials led
0
Research papers it led
5
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.4%
Papers led per year
2021: 0020212022: 2220222023: 1120232024: 1120242025: 112025

Hospitals counted here

  1. Peking Union Medical College Hospital2
  2. Children's Hospital, Peking Union Medical College2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Hirschsprung disease

先天性巨结肠
1.2%Leads about 1 in 81 of China's research papers on Hirschsprung disease ▲ from 0.7%

Led 2 of 161 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (13.0%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.3%
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 112025

Hospitals counted here

  1. Peking Union Medical College Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Inherited epidermolysis bullosa

遗传性大疱性表皮松解症
7.1%Leads about 1 in 14 of China's research papers on Inherited epidermolysis bullosa ▲ from 4.8%

Led 4 of 56 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (12.5%).

Run this PubMed search

Open trials led
0
Research papers it led
4
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.5%
Papers led per year
2021: 1120212022: 1120222023: 1120232024: 0020242025: 112025

Hospitals counted here

  1. Peking Union Medical College Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Hereditary angioedema

遗传性血管性水肿
31.2%Leads about 1 in 3 of China's research papers on Hereditary angioedema ▼ from 57.1%

Led 10 of 32 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (31.2%).

Run this PubMed search

Open trials led
0
Research papers it led
10
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
1.8%
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 332025

Hospitals counted here

  1. Peking Union Medical College Hospital10

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov